- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06934226
Um estudo para avaliar a eficácia e a segurança de JNJ-77242113 em comparação com placebo e ustekinumab em participantes com psoríase de placa moderada a grave (ICONIC-ASCEND)
Um estudo com comparador multicêntrico, randomizado, duplo-cego, controlado por placebo e controlado por placebo para avaliar a eficácia e a segurança da JNJ-77242113 para o tratamento de participantes com psoríase de placa moderada a grave
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Augsburg, Alemanha, 86179
- Klinikum Augsburg
-
Bad Bentheim, Alemanha, 48455
- Fachklinik Bad Bentheim
-
Berlin, Alemanha, 10789
- ISA - Interdisciplinary Study Association GmbH
-
Bonn, Alemanha, 53127
- Universitatsklinikum Bonn
-
Bramsche, Alemanha, 49565
- Studienzentrum an der Hase GbR
-
Darmstadt, Alemanha, 64283
- Rosenpark Research GmbH
-
Dresden, Alemanha, 01307
- Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
-
Friedrichshafen, Alemanha, 88045
- Derma-Study-Center Friedrichshafen GmbH
-
Kiel, Alemanha, 24105
- Universitaetsklinikum Schleswig Holstein Campus Kiel
-
Langenau, Alemanha, 89129
- Studienzentrum Dr Schwarz Germany
-
Mahlow, Alemanha, 15831
- Dermatologie Mahlow
-
Mainz, Alemanha, 55128
- Gemeinschaftspraxis Dres. Quist
-
Münster, Alemanha, 48149
- Universitaetsklinikum Muenster
-
Witten, Alemanha, 58453
- Hautarztpraxis
-
-
-
-
-
Barrio Gral Paz Cba Capital, Argentina, X5000
- Consultora Integral de Salud SRL
-
Buenos Aires, Argentina, B1643CRO
- Instituto Medico De Alta Complejidad (IMAC)
-
Buenos Aires, Argentina, C1417EYG
- Mindout Research
-
Buenos Aires, Argentina, C1425
- Instituto de Neumonologia y Dermatologia
-
CABA, Argentina, C1061AAS
- CIPREC
-
CABA, Argentina, C1199ABB
- Hospital Italiano de Buenos Aires
-
CABA, Argentina, C1055AAO
- Buenos Aires Skin
-
CABA, Argentina, C1056ABH
- Investigaciones Medicas IMOBA SRL
-
CABA, Argentina, C1128
- Mautalen Salud e Investigacion
-
Caba, Argentina, C1122AAF
- Halitus Instituto Medico S.A. - Dermatologia y Estetica
-
Rosario, Argentina, S2000DBS
- Instituto De Especialidades De La Salud SRL
-
San Fernando, Argentina, B1646
- MR Medicina Reumatologica
-
San Miguel de Tucumán, Argentina, T4000
- Instituto de Investigaciones Medicas Tucuman
-
-
-
-
-
Clayton, Austrália, 3168
- Monash Medical Centre
-
Coorparoo, Austrália, 4151
- Cornerstone Dermatology
-
Greenslopes, Austrália, 4120
- Veracity Clinical Research
-
Kogarah, Austrália, 2217
- Premier Specialists
-
Melbourne, Austrália, 3004
- The Alfred Hospital
-
Melbourne, Austrália, 3050
- Royal Melbourne Hospital
-
Mitcham, Austrália, 3132
- ISHI dermatology
-
Westmead, Austrália, 2145
- Westmead Hospital
-
-
-
-
-
Brussels, Bélgica, 1090
- UZ Brussel
-
Ghent, Bélgica, 9000
- Ghent University Hospital
-
Ghent, Bélgica, 9000
- AZ St. Lucas
-
Leuven, Bélgica, 3000
- Universitair Ziekenhuis Leuven
-
Liège, Bélgica, 4000
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
Maldegem, Bélgica, 9990
- Dermatologie Maldegem
-
-
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canadá, A1E 1V4
- Skincare Studio Inc Dermatology Clinical Trials
-
-
Ontario
-
Ajax, Ontario, Canadá, L1S7K8
- CCA Medical Research Corporation
-
Barrie, Ontario, Canadá, L4M 7G1
- SimcoDerm Medical and Surgical Dermatology Centre
-
Hamilton, Ontario, Canadá, L8N 1Y2
- Dermatrials Research
-
London, Ontario, Canadá, N6A 5R9
- Lovegrove Dermatology
-
Markham, Ontario, Canadá, L3P 1X3
- Lynderm Research Inc.
-
Waterloo, Ontario, Canadá, N2J 1C4
- Alliance Clinical Trials
-
-
Quebec
-
Montreal, Quebec, Canadá, H2X 2V1
- Innovaderm Research Inc.
-
Québec, Quebec, Canadá, G1W 4R4
- The Centre de recherche Saint-Louis
-
-
-
-
-
Aalborg, Dinamarca, 9100
- Aalborg Sygehus Syd
-
Aarhus, Dinamarca, 8200
- Aarhus University Hospital
-
Hellerup, Dinamarca, 2900
- Gentofte Hospital
-
København NV, Dinamarca, 2400
- Bispebjerg Hospital
-
Odense, Dinamarca, 5000
- Odense University Hospital
-
Roskilde, Dinamarca, 4000
- Sjællands University hospital
-
-
-
-
-
Alicante, Espanha, 03010
- Hosp. Gral. Univ. Dr. Balmis
-
Barakaldo, Espanha, 48902
- Hosp. Univ. de Cruces
-
Barcelona, Espanha, 08036
- Hosp. Clinic de Barcelona
-
Granada, Espanha, 18016
- Hosp. Univ. San Cecilio
-
Madrid, Espanha, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Espanha, 28006
- Hosp. Univ. de La Princesa
-
Madrid, Espanha, 28002
- Grupo Dermatologico Y Estetico Pedro Jaen
-
Manises, Espanha, 46940
- Hosp. de Manises
-
Santiago Compostela, Espanha, 15706
- Hosp. Clinico Univ. de Santiago
-
Seville, Espanha, 41009
- Hosp. Virgen Macarena
-
Seville, Espanha, 41014
- Hosp. Ntra. Sra. de Valme
-
Valencia, Espanha, 46026
- Hosp. Univ. I Politecni La Fe
-
Villajoyosa, Espanha, 03570
- Hosp. de La Marina Baixa
-
Zaragoza, Espanha, 50009
- Hosp. Clinico Univ. Lozano Blesa
-
Zaragoza, Espanha, 50009
- Hosp. Univ. Miguel Servet
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35244
- Cahaba Research Inc
-
-
California
-
Encinitas, California, Estados Unidos, 92024
- California Dermatology & Clinical Research Institute
-
Encino, California, Estados Unidos, 91436
- T Joseph Raoof Md Inc
-
Fountain Valley, California, Estados Unidos, 92708
- First OC Dermatology
-
Oceanside, California, Estados Unidos, 92056
- Dermatologist Medical Group of North County, Inc.
-
Rocklin, California, Estados Unidos, 95765
- NorCal Clinical Research
-
Sacramento, California, Estados Unidos, 95815
- Integrative Skin Science and Research
-
San Diego, California, Estados Unidos, 92103
- MedDerm Associates
-
Santa Ana, California, Estados Unidos, 92701
- Southern California Dermatology
-
Sylmar, California, Estados Unidos, 91342
- Olive View-UCLA Education & Research Institute
-
-
Connecticut
-
Farmington, Connecticut, Estados Unidos, 06030
- University of Conn Health Center
-
-
Florida
-
Miami, Florida, Estados Unidos, 33155
- Bioclinical Research Alliance Inc.
-
Miami, Florida, Estados Unidos, 33126
- Driven Research LLC
-
Ocala, Florida, Estados Unidos, 34470
- Renstar Medical Research
-
Tampa, Florida, Estados Unidos, 33613
- Forcare Clinical Research Inc
-
-
Georgia
-
Alpharetta, Georgia, Estados Unidos, 30022
- Hamilton Research LLC
-
-
Illinois
-
Skokie, Illinois, Estados Unidos, 60076
- Northshore Medical Group
-
-
Indiana
-
Plainfield, Indiana, Estados Unidos, 46168
- Indiana Clinical Trial Center
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa
-
-
Kentucky
-
Bowling Green, Kentucky, Estados Unidos, 42104
- Equity Medical
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02111
- Tufts Medical Center
-
Brighton, Massachusetts, Estados Unidos, 02135
- Metro Boston Clinical Partners
-
-
Michigan
-
Caledonia, Michigan, Estados Unidos, 49316
- The Derm Institute of West Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
Fort Gratiot, Michigan, Estados Unidos, 48059
- Hamzavi Dermatology
-
Troy, Michigan, Estados Unidos, 48084
- Somerset Skin Centre
-
-
Minnesota
-
New Brighton, Minnesota, Estados Unidos, 55112
- Minnesota Clinical Study Center
-
-
Missouri
-
Kirksville, Missouri, Estados Unidos, 63501
- Cleaver Dermatology
-
Saint Joseph, Missouri, Estados Unidos, 64506
- MediSearch Clinical Trials
-
-
New York
-
New York, New York, Estados Unidos, 10075
- Sadick Research Group
-
New York, New York, Estados Unidos, 10028
- Mount Sinai Doctors Dermatology
-
-
North Carolina
-
Wilmington, North Carolina, Estados Unidos, 28405
- Wilmington Dermatology Center
-
-
Ohio
-
Boardman, Ohio, Estados Unidos, 44512
- Optima Research
-
Mayfield Heights, Ohio, Estados Unidos, 44124
- Apex Dermatology Mayfield Heights
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97210
- Oregon Dermatology and Research Center
-
Portland, Oregon, Estados Unidos, 97201
- Oregon Medical Research Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19114
- Clinical Research Philadelphia
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- UPMC Department of Dermatology
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos, 57702
- Health Concepts
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37211
- Advanced Research Experts PLLC
-
-
Texas
-
Arlington, Texas, Estados Unidos, 76011
- Arlington Research Center, Inc.
-
Dallas, Texas, Estados Unidos, 75231
- Modern Research Associates PLLC
-
Houston, Texas, Estados Unidos, 77004
- Center for Clinical Studies 1
-
San Antonio, Texas, Estados Unidos, 78218
- Texas Dermatology and Laser Specialists
-
San Antonio, Texas, Estados Unidos, 78213
- Progressive Clinical Research
-
Webster, Texas, Estados Unidos, 77598
- Center for Clinical Studies
-
-
Utah
-
West Valley City, Utah, Estados Unidos, 84120
- Kalo Clinical Research
-
-
Washington
-
Mill Creek, Washington, Estados Unidos, 98012
- Frontier Derm Partners CRO, LLC
-
-
-
-
-
Budapest, Hungria, 1036
- Obudai Egeszsegugyi Centrum Kft
-
Budapest, Hungria, 1152
- Uno Medical Trials Ltd.
-
Debrecen, Hungria, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Debrecen, Hungria, 4031
- Derma-B Kft
-
Gyula, Hungria, 5700
- Synexus Magyarorszag Kft
-
Gyöngyös, Hungria, 3200
- Gyongyosi Bugat Pal Korhaz
-
Hódmezővásárhely, Hungria, 6800
- Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
-
Kaposvár, Hungria, 7400
- Somogy Varmegyei Kaposi Mor Oktato Korhaz
-
Kecskemét, Hungria, 6000
- Bacs-kiskun Megyei Korhaz
-
Szolnok, Hungria, 5000
- Allergo-Derm Bakos Kft.
-
Veszprém, Hungria, 8200
- Medmare Egeszsegugyi Es Szolgaltato Bt.
-
-
-
-
-
Bialystok, Polônia, 15 375
- Specderm Poznanska sp j
-
Bialystok, Polônia, 15-351
- Osteo-Medic s.c A. Racewicz, J Supronik
-
Elblag, Polônia, 82 300
- Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
-
Katowice, Polônia, 40 568
- Care Clinic Sp z o o
-
Krakow, Polônia, 30 002
- Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
-
Lodz, Polônia, 90-265
- Dermed Centrum Medyczne Sp z o o
-
Olsztyn, Polônia, 10-117
- Etyka Osrodek Badan Klinicznych
-
Poznan, Polônia, 60 529
- SOLUMED Centrum Medyczne
-
Skierniewice, Polônia, 96 100
- Velocity Nova Sp z o o
-
Warsaw, Polônia, 02 661
- Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
-
Warsaw, Polônia, 02 953
- Klinika Ambroziak Dermatologia
-
Wroclaw, Polônia, 52 416
- Centrum Medyczne Oporow
-
Wroclaw, Polônia, 51 685
- WroMedica I Bielicka A Strzalkowska s c
-
-
-
-
-
Guimarães, Portugal, 4835 044
- Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
-
Leiria, Portugal, 2410 197
- Unidade Local De Saude Da Regiao De Leiria Epe
-
Lisbon, Portugal, 1169 050
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon, Portugal, 1998 018
- Hosp. Cuf Descobertas
-
Porto, Portugal, 4099 001
- Ulssa Hosp. Santo Antonio
-
-
-
-
-
Dudley, Reino Unido, DY1 2HQ
- Dudley Group NHS Foundation Trust
-
Harrow, Reino Unido, HA1 3UJ
- London North West University Healthcare NHS Trust
-
Kings Lynn, Reino Unido, PE30 4ET
- The Queen Elizabeth Hospital NHS Foundation Trust
-
London, Reino Unido, SE1 9RT
- Guys and St Thomas NHS Foundation Trust
-
Reading, Reino Unido, RG1 5AN
- Royal Berkshire Hospital
-
Salford, Reino Unido, M6 8HD
- Salford Royal Hospital
-
Southampton, Reino Unido, So166yd
- University Hospital Southampton
-
Wakefield, Reino Unido, WF1 4DG
- Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
-
-
-
-
-
Feldkirch, Áustria, 6800
- LKH Feldkirch
-
Linz, Áustria, 4020
- Kepler Universitatsklinikum GmbH
-
Sankt Pölten, Áustria, 3100
- Universtitatsklinikum St Poelten
-
Vienna, Áustria, 1090
- Allgemeines Krankenhaus der Stadt Wien
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
- Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
- Total psoriasis area and severity index (PASI) >=12 at screening and baseline
- Total investigator global assessment (IGA) >=3 at screening and baseline
- Candidate for phototherapy or systemic treatment for plaque psoriasis
Exclusion Criteria:
- Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
- Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
- Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
- Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm 1: JNJ 77242113
Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind. |
JNJ-77242113 will be administered orally. Matching placebo will be administered subcutaneously. |
|
Comparador de Placebo: Arm 2: Placebo
Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104. |
JNJ-77242113 will be administered orally. Matching placebo will be administered subcutaneously. Matching placebo will be administered orally. |
|
Comparador Ativo: Arm 3: Ustekinumab
Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28. |
JNJ-77242113 will be administered orally. Matching placebo will be administered orally. Ustekinumab will be administered subcutaneously.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
Prazo: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Prazo: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
Prazo: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Prazo: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
Prazo: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
Prazo: Week 28
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
Prazo: Week 28
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
Prazo: Week 28
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 28
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
Prazo: Week 16
|
PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
Prazo: Week 16
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Prazo: Up to Week 108
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important. |
Up to Week 108
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
Prazo: Week 16
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Prazo: Baseline up to Week 16
|
DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Baseline up to Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
Prazo: Week 16
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
Prazo: Baseline up to Week 16
|
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA. |
Baseline up to Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
Prazo: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
Prazo: Baseline up to Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
Prazo: Baseline up to Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
Prazo: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
Prazo: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
Prazo: Baseline up to Week 28
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
Prazo: Week 28
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
Prazo: Baseline up to Week 16
|
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA. |
Baseline up to Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
Prazo: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
Prazo: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Prazo: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 77242113PSO3006
- 77242113PSO3006 (Outro identificador: Janssen Research & Development, LLC)
- 2024-515706-77-00 (Identificador de registro: EUCT number)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .